Recently non-HDL cholesterol has been recommended to replace LDL cholesterol in the clinical management of dyslipidaemia routinely in general medical practice. The authors claim this is misguided.
Research suggests adherence to lifelong pharmacological and lifestyle treatment by people with FH is poor. This study explores the qualitative research to identify enablers and barriers to treatment adherence.
To describe demographic characteristics, current local clinical management and outcomes for patients with familial hypercholesterolaemia (FH) managed at the Royal Brompton and Harefield NHS Foundation Trust (RBHT), a specialist UK tertiary cardiac centre.
Source: Journal of Clinical Lipidology and Metabolic Disorders
